SciELO - Scientific Electronic Library Online

 
vol.68 issue3Conditions of drugs transportation in international missions of the Armed Forces: Design of a specific stability study of operations author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Indicators

Related links

  • On index processCited by Google
  • Have no similar articlesSimilars in SciELO
  • On index processSimilars in Google

Share


Sanidad Militar

Print version ISSN 1887-8571

Abstract

VALENTIN QUIROGA, J. et al. Kill the Killers: Natural Killer cells therapy against paediatric refractory solid tumours. Sanid. Mil. [online]. 2012, vol.68, n.3, pp.141-146. ISSN 1887-8571.  https://dx.doi.org/10.4321/S1887-85712012000300003.

Introduction: Refractory solid tumours lead children deaths. To change this statement, new treatments should be developed. Natural Killer cells constitute the first line of defence against tumour cells. We propose a new strategy for antitumor cell therapy in children with refractory solid malignancies: IL-15 stimulated NK cells. Patients and methods: 22 paediatric patients suffering refractory solid tumours participate in this study. We compare NK cell subsets and K562 cytotoxicity in patients and sex-age pair's healthy controls. We use multiparametric flow and time-resolved fluorescent, respectively. In immunocompromised mice we developed an aggressive human metastatic neuroblastoma model and IL-15 stimulated NK cells rescue. Results: Patients had higher NK bright cells subset and lower NK cytotoxicity than healthy controls. IL-15 stimulated NK cells improved NK cell cytotoxicity in vitro and decreased tumour burden in vivo. Conclusions: IL-15 stimulated NK cells may constitute a new cell therapy tool for paediatric refractory tumours.

Keywords : Natural Killer cells (NK); interleucina 15 (IL-15); refractory solid tumours.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )

 

Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License